Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome

Phase

Condition

Urticaria

Acne

Pneumonia

Treatment

N/A

Clinical Study ID

NCT02550080

SDPIDV-DDS-001

Ages 18-65
All Genders

Study Summary

This Study is to evaluate the utility of prospective HLA-B1301 screening on the incidence of dapsone hypersensitivity syndrome (DHS) in 3130 previously Dapsone(DDS)-naive patients. Those patients include allergic cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration. The study has two (co-primary) objectives: i) to determine if screening for HLA-B1301 prior to DDS-containing treatment results in a lower incidence of clinically-suspected DHS versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B1301 prior to DDS-containing treatment results in a significantly lower incidence of immunologically-confirmed DHS versus current standard of care (no genetic screening or patch testing). The study consists of up to a 5-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected DHS and a subset of DDS-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening: Case). Subjects identified as HLA-B1301 positive in the prospective Genetic Screening Arm will not receive dapsone and will be excluded from further study. Subjects who experience suspected DHS during the 6-week observation would be withdrawn from dapsone and undergo EPT patch testing 6 weeks later.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Diagnosed with cutaneous vasculitis, urticaria, psoriasis, acne, bullous skindiseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patientswho need dapsone administration.
Subjects are dapsone-naive.
All subjects must have a clinical need for treatment with dapsone that precedes thedecision to participate in the study.
All subjects are willing to complete the 6-weeks period clinical trial.
All subjects are written informed consent.

Exclusion

Exclusion Criteria:

Has previously received Dapsone therapy.
The subject or any of their healthcare providers is aware of the subjects HLA type.
Has been diagnosed with Glucose-6-phosphate dehydrogenase deficiency or methemoglobinreductase deficiency
Satisfies any contraindications or restrictions to Dapsone therapy as listed in theproduct labels.
Current severe illness, including heart, liver and renal failure, major organallograft, malignancy requiring parenteral chemotherapy that can not be discontinuedfor the duration of the trial, or any other conditions which, in the opinion of theInvestigator, would make the patient unsuitable for the study.
Any laboratory abnormality at Screening which, in the opinion of the Investigator,should preclude the subject's participation in the study [alanine aminotransferase (ALT), glutamic oxaloacetic transaminase(ALT), et al).
Pregnant women or women who are breastfeeding.
Subject is, in the opinion of the Investigator, unable to complete the 6 weekObservation period and the EPT assessments as required.
A positive result for HLA-B*1301 in those subjects randomised to the genetic screeningarm.

Study Design

July 01, 2015

May 31, 2019

Connect with a study center

Shandong Provincial Institute of Dermatology and Venereology
Jinan, Shandong 250000
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.